Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7800376 | 0.86 | LMNA (0.34) | KMT2ALMNAMAPTSMYD2HTR2A | |
| SCHEMBL7787331 | 0.84 | CYP1A2 (0.44) | KMT2AHTTPDGFRBKITKDR | |
| SCHEMBL7802510 | 0.84 | ALDH1A1 (0.38) | KMT2ADRD3PDGFRBKITKDR | |
| SCHEMBL6036129 | 0.81 | SLC6A4 (0.46) | KMT2ALMNAMAPTHTR2AHTR2C | |
| SCHEMBL6036070 | 0.81 | LMNA (0.47) | LMNAHTR2AHTR2CSLC6A4DRD3 | |
| SCHEMBL6036120 | 0.80 | KMT2A (0.49) | KMT2ALMNAMAPTSMYD2HTR2A | |
| SCHEMBL7780236 | 0.79 | MAPT (0.35) | LMNAMAPTPDGFRBKITKDR | |
| SCHEMBL6035652 | 0.79 | HTR4 (0.46) | KMT2ASMYD2HTR2AHTR2CSLC6A4 | |
| SCHEMBL6035840 | 0.79 | LMNA (0.48) | KMT2ALMNASMYD2 | |
| SCHEMBL6035188 | 0.78 | ALDH1A1 (0.50) | KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140067-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140062-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140291-A1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |